Our current research suggests that visfatin may play a beneficial role in the proliferation of multiple myeloma (MM) cells, which is consistent with findings from studies on breast cancer, endometrial cancer, and renal cell carcinoma [31–33]. This evidence concerns the gene NAMPT and renal cell carcinoma.